Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderately to severely active rheumatoid arthritis. Sold as Actemra. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Tocilizumab (sold as Actemra), first approved Jan 8, 2010, with 22 new uses approved and 0 published complete response letters.
First approved: Jan 8, 2010
Applications: 2
New uses approved: 22
Complete response letters: 0
Medicare spending, 2025: $929M
Orphan exclusivity until: Mar 4, 2028
First approved in the EU: Jan 16, 2009
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
ActemraDrugs with a new indication for the treatment of cytokine release syndrome induced by the treatment for malignant tumor. · Chugai Pharmaceutical Co., Ltd. · Sep 25, 2023
ActemraDrugs with a new indication and a new dosage for the treatment of pneumonia caused by SARS- CoV-2 (only for the patients requiring supplemental oxygen). · Chugai Pharmaceutical Co., Ltd. · Jan 21, 2022 · Review report
ActemraDrugs with a new additional indication and a new dosage for the treatment of adult Still's disease in patients who have not responded sufficiently to… · Chugai Pharmaceutical Co., Ltd. · May 22, 2019 · Review report
ActemraDrugs with a new additional indication and a new dosage for the treatment of cytokine release syndrome induced by tumor-specific T-cell infusion therapy. · Chugai Pharmaceutical Co., Ltd. · Mar 26, 2019
ActemraDrugs with new additional indications and a new dosage for the treatment of Takayasu arteritis and giant cell arteritis in patients who have not responded… · Chugai Pharmaceutical Co., Ltd. · Aug 25, 2017 · Review report
ActemraDrugs with a new dosage indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not… · Chugai Pharmaceutical Co., Ltd. · Jun 26, 2017 · Review report
Actemra, new approvalDrugs with a new route of administration indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients… · Chugai Pharmaceutical Co., Ltd. · Mar 25, 2013
Actemra, new approvalDrugs with a new indication and a new dosage in a new dosage form for the treatment of rheumatoid arthritis (including prevention of structural damage of… · Chugai Pharmaceutical Co., Ltd. · Apr 16, 2008 · Review report
Clinical Trials
146 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
